# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
On April 15, 2024, Sung Lee, Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc. (the "Company&...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $110 pri...
– Over 60 participants dosed in two additional cohorts; initial data expected in the second quarter –– Approximately 50% of par...
Shares of MercadoLibre, Inc. (NASDAQ: MELI) fell sharply during Friday’s session after the company reported fourth-quarter fin...
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 100 points on Friday.
Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(0.86) per share which beat the analyst consensus estimate of $(1....
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on reve...